This effort reflects a structural shift toward including older populations, long overlooked despite their growing vulnerability to cognitive decline. Prior animal studies suggest psilocybin increases synaptic connections in key brain regions, but older adults have comprised only about 1.4% of subjects in past psychedelics trials. Montana businesses might watch this research with interest, as cognitive health is critical to workforce longevity in rural and aging communities. If psilocybin proves to promote healthy brain aging, it could influence future healthcare approaches, especially where access to traditional cognitive therapies is limited by geography or resources. Tripping into old age: Can psychedelics protect the aging brain?